Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Rhea-AI Summary

Takeda gains approval for ADZYNMA, a groundbreaking treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in Japan. ADZYNMA is the first recombinant ADAMTS13 enzyme replacement therapy for cTTP, addressing acute events and chronic symptoms. The approval is based on positive interim analysis results from a Phase 3 trial, showcasing efficacy, safety, and tolerability. ADZYNMA demonstrated a significant reduction in acute TTP events compared to plasma-based therapies, with a lower incidence of treatment-related adverse events.

Insights

Medical Research Analyst

The approval of ADZYNMA by the Japanese Ministry of Health for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) represents a significant advancement in the field of rare blood disorders. The provision of a recombinant ADAMTS13 enzyme as a replacement therapy is a novel approach that directly targets the underlying cause of cTTP, which is a deficiency in the ADAMTS13 enzyme. This treatment modality is distinct from the traditional plasma-based therapies that have been the mainstay for managing the condition.

From a medical research perspective, the efficacy data showing no acute TTP events in patients treated with ADZYNMA during the interim analysis is promising. This suggests a potential improvement in patient outcomes compared to plasma-based therapies. Additionally, the lower incidence of treatment-emergent adverse events (TEAEs) in patients receiving ADZYNMA compared to those receiving plasma-based therapy is noteworthy, as it indicates a favorable safety profile for the new treatment. These factors could lead to an increased demand for the drug and potentially influence Takeda's market share in the rare disease treatment sector.

Healthcare Economist

As a healthcare economist, I would highlight that the introduction of ADZYNMA could have significant economic implications for the healthcare system in Japan and potentially globally. cTTP, being an ultra-rare condition, often requires expensive and long-term treatments. The new enzyme replacement therapy could potentially reduce the frequency of acute events and hospitalizations, leading to a decrease in overall healthcare costs associated with managing cTTP.

Furthermore, the pricing strategy for ADZYNMA will be a critical factor in its economic impact. If priced competitively, it could encourage a shift from plasma-based therapies, resulting in cost savings for healthcare providers and insurers. However, the cost-effectiveness of the drug will need to be evaluated in the context of its long-term efficacy and safety, which will become clearer as more data from the continuation study becomes available.

Pharmaceutical Market Analyst

From a market analysis standpoint, Takeda's announcement that the approval of ADZYNMA does not affect their FY2023 consolidated forecast suggests that the immediate financial impact of the drug's introduction may be limited. This could be due to the ultra-rare nature of cTTP, resulting in a relatively small patient population. However, the approval of a first-in-class treatment for a condition with high unmet medical need could position Takeda as a leader in the rare disease space, potentially enhancing its reputation and providing leverage for future negotiations with healthcare providers and payers.

In the long term, the success of ADZYNMA may hinge on its adoption by healthcare professionals, patient access programs and reimbursement policies. The drug's market penetration and revenue generation will likely be gradual, as awareness and confidence in the treatment grow within the medical community. Takeda's strategic planning and post-marketing efforts will be critical in determining the market trajectory of ADZYNMA.

• cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms
• ADZYNMA (apadamtase alfa /cinaxadamtase alfa) is the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for People with cTTP

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.¹ ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.

cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.² It is associated with acute events and debilitating chronic symptoms or thrombotic thrombocytopenic purpura (TTP) manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, headache and abdominal pain.^2,3,4 When left untreated, acute TTP events have a mortality rate of >90%.^2,4

“The approval of ADZYNMA is an important milestone for people living with cTTP in Japan, who had limited treatment options and now have the first treatment option specifically approved to treat this ultra-rare condition,” said Yasushi Kajii, Head, R&D Japan Region at Takeda. “Developing innovative treatments that make a difference in the lives of patients is at the heart of what we do. With this approval, we are proud to support the cTTP community with new possibilities and continue our 70-plus year commitment to the rare disease community.”

The approval is supported by the totality of the evidence provided from an interim analysis of efficacy, pharmacokinetic, safety and tolerability data from the first randomized, controlled, open-label, crossover Phase 3 trial in cTTP patients ages 12-68, (281102 NCT03393975) which includes five Japanese patients and supported by long-term safety and efficacy data from a continuation study (TAK-755-3002 NCT04683003).⁵ At the time of interim analysis, no patient experienced an acute TTP event while receiving ADZYNMA prophylactic treatment (n=37), while there was one acute TTP event in a patient receiving plasma-based therapies (n=38) during the Phase 3 study-controlled comparison periods 1 and 2.⁶

Treatment-emergent adverse events (TEAEs) assessed as treatment-related during periods 1 and 2 were reported in 10.3% of patients receiving ADZYNMA compared to 50% of patients receiving plasma-based therapy.⁶ TEAEs observed in ADZYNMA group were constipation, ADAMTS13 activity abnormal, headache, pruritus, and hypertension (1 subject each). In Period 3, the incidence of TEAEs was 2.8% (1/36) in this drug group: nausea and headache (1 subject each).⁶

This approval does not result in any changes to Takeda’s consolidated forecast for the fiscal year ending March 31, 2024 (FY2023).

ABOUT ADZYNMA (apadamtase alfa /cinaxadamtase alfa)

ADZYNMA (apadamtase alfa /cinaxadamtase alfa) is a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” ADAMTS13 (rADAMTS13) indicated for congenital thrombotic thrombocytopenic purpura (cTTP) in Japan.¹ ADZYNMA can be used for prophylactic or on-demand enzyme replacement therapy (ERT) in patients 12 years of age and older.

ADZYNMA is also approved by the U.S. Food and Drug Administration (FDA) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).⁷

ADZYNMA was previously granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment and prevention of TTP, including its acquired idiopathic and secondary forms, and by the European Medicines Agency (EMA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of TTP.

ADZYNMA (apadamtase alfa /cinaxadamtase alfa) Product Overview in Japan

Brand Name	ADZYNMA Intravenous Injection 1500
Generic Name	apadamtase alfa /cinaxadamtase alfa
Indications	Congenital thrombotic thrombocytopenic purpura (cTTP)
Dosage and Administration	This drug should be reconstituted with 5 mL of the supplied solvent, and the reconstituted solution should be slowly injected intravenously at a rate of 2~4 mL/min. For prophylactic treatment The usual dosage for adults and children aged ≥ 12 years is 40 IU/kg (body weight) every other week. A dose of 40 IU/kg (body weight) may be administered once weekly depending on the dose and regimen of prior therapy or clinical response. For on-demand treatment The usual initial dosage for adults and children aged ≥ 12 years is 40 IU/kg (body weight) on Day 1 as the initial dose for measures such as management of thrombotic thrombocytopenic purpura symptoms. Patients will receive 20 IU/kg (body weight) daily on Day 2 and 15 IU/kg (body weight) daily from Day 3 until Day 2 after resolution of symptoms.

ABOUT cTTP

cTTP is an ultra-rare, chronic and debilitating clotting disorder associated with life-threatening acute events and debilitating chronic symptoms, or TTP manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, headache and abdominal pain.^8,9 TTP has an estimated prevalence of 2-6 cases/million, though the true prevalence is unknown. The inherited form of the disease, cTTP, accounts for ≤5% of TTP patients.^9,10,11 It develops due to deficiency in ADAMTS13, a von Willebrand factor (VWF) cleaving protease, which results in the accumulation of ultra-large VWF multimers in the blood.⁸ The accumulation of ultra-large VWF multimers leads to uncontrolled platelet aggregation and adhesion.^3,9 This can lead to abnormal clotting in the small blood vessels of the body and is associated with microangiopathic hemolytic anemia and low platelet levels (thrombocytopenia).³

cTTP has both acute and chronic manifestations (including stroke and cardiovascular disease) and when left untreated, acute TTP events have a mortality rate of >90%.^3,11 cTTP can also cause ongoing widespread organ damage and other co-morbidities resulting from an ADAMTS13-deficient state.^4,9,12,13

Important Safety Information

Apadamtase alfa /cinaxadamtase alfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients of this drug.

Hypersensitivity Reactions: Allergic-type hypersensitivity, including anaphylactic reactions, may occur with apadamtase alfa /cinaxadamtase alfa. Patients should be educated about early signs of hypersensitivity such as tachycardia, chest tightness, wheezing and/or acute respiratory distress, hypotension, generalized urticaria, pruritus, rhinoconjunctivitis, angioedema, lethargy, nausea, vomiting, paresthesia, and restlessness. If signs and symptoms of severe allergic reactions occur, immediately discontinue administration of apadamtase alfa /cinaxadamtase alfa and provide appropriate supportive care.

Immunogenicity: There is a potential for immunogenicity with apadamtase alfa /cinaxadamtase alfa. Patients may develop neutralizing antibodies to ADAMTS13, which could potentially result in a decreased or lack of response to ADAMTS13. Patients may develop antibodies to host cell proteins which could potentially result in adverse reactions. There are no data on immunogenicity with apadamtase alfa /cinaxadamtase alfa or to host cell proteins in previously untreated patients (subjects naïve to plasma-based products).

Adverse Reactions: The most commonly observed adverse reactions (>5% of subjects) associated with apadamtase alfa /cinaxadamtase alfa are headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting.

Use in Specific Populations: This drug should be administered to pregnant women or possibly pregnant women only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A, Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including information for patients.

ABOUT TAKEDA

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References:

1. ADZYNMA Package Insert in Japan.
2. Van Dorland H et al. Haematologica. 2019;104:2107-16.
3. Chiasakul T and Cuker A. Am Soc Hematol. 2018;2018(1):530–538.
4. Joly BS et al., Blood. 2017;129(21):2836–2846.
5. ClinicalTrials.gov A Study of TAK-755 in Participants with Congenital Thrombotic Thrombocytopenic Purpura Available at: https://clinicaltrials.gov/ct2/show/NCT04683003. Accessed March 2024.
6. Scully M, et al. Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura. ISTH 2023 Congress; June 24-28, 2023. Abstract OC 14.1.
7. ADZYNMA (ADAMTS13, recombinant-krhn) Prescribing Information; 2023.
8. Alwan F, et al., Blood. 2019;133:1644-51.
9. Kremer Hovinga JA, et al. Nat Rev Dis Primers. 2017;3:17020.
10. Kremer Hovinga JA, George JN. Hereditary Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;381(17):1653-1662.
11. Orpha.net. Congenital thrombotic thrombocytopenic purpura. Available at: https://www.orpha.net/en/disease/detail/93583?name=Congenital%20thrombotic%20thrombocytopenic%20purpura&mode=name. Accessed March 2024.
12. Zheng XL et al. J Thromb Haemost. 2020;18(10):2486-95.
13. Sukumar S, et al. J Clin Med. 2021;10:536.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240325490780/en/

MEDIA:

Japanese Media

Shigeyuki Matsui

shigeyuki.matsui@takeda.com

U.S. and International Media

Megan Ostrower

megan.ostrower@takeda.com

Source: Takeda Pharmaceutical Company Limited

FAQ

What is the significance of the approval for ADZYNMA by the Japanese Ministry of Health, Labour and Welfare?

The approval marks a milestone in treating congenital thrombotic thrombocytopenic purpura (cTTP) in Japan with the first recombinant ADAMTS13 enzyme replacement therapy.

What is cTTP, and how does ADZYNMA address this condition?

cTTP is an ultra-rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. ADZYNMA is designed to replace the deficient enzyme, addressing acute events and chronic symptoms associated with cTTP.

What data supported the approval of ADZYNMA?

The approval is based on positive interim analysis results from a Phase 3 trial (NCT03393975) in cTTP patients ages 12-68. Long-term safety and efficacy data from a continuation study (NCT04683003) also supported the approval.

How did ADZYNMA perform compared to plasma-based therapies in the Phase 3 trial?

During the Phase 3 trial, no patient experienced an acute TTP event while receiving ADZYNMA prophylactic treatment, compared to one acute event in a patient receiving plasma-based therapies. ADZYNMA also showed a lower incidence of treatment-related adverse events.

What impact does the approval of ADZYNMA have on Takeda's financial forecast?

The approval does not result in any changes to Takeda's consolidated forecast for the fiscal year ending March 31, 2024 (FY2023).